VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Nimer on the Biggest Challenges of MDS

Stephen D. Nimer, MD
Published: Friday, May 01, 2015



Stephen D. Nimer, MD, Director, Professor of Medicine, Sylvester Comprehensive Cancer Center discusses the challenges of treating myelodysplastic syndromes (MDS).

Patients with MDS have a wide variety of survival outcome; some may live for years while others only for months. Understanding from the beginning the expected progression of each individual patient it is critical, says Nimer.

Although there are three FDA approved drugs for MDS, none are curative and when patients progress on these drugs the prognosis is poor. New drug are needed as well as additional understanding on how stem-cell transplantation and drug therapies can be combined, says Nimer.



Stephen D. Nimer, MD, Director, Professor of Medicine, Sylvester Comprehensive Cancer Center discusses the challenges of treating myelodysplastic syndromes (MDS).

Patients with MDS have a wide variety of survival outcome; some may live for years while others only for months. Understanding from the beginning the expected progression of each individual patient it is critical, says Nimer.

Although there are three FDA approved drugs for MDS, none are curative and when patients progress on these drugs the prognosis is poor. New drug are needed as well as additional understanding on how stem-cell transplantation and drug therapies can be combined, says Nimer.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x